Hasil Pencarian - Francesca Aroldi

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Current Role of Minimally Invasive Radical Cholecystectomy for Gallbladder Cancer

    Current Role of Minimally Invasive Radical Cholecystectomy for Gallbladder Cancer oleh Giuseppe Zimmitti, Alberto Manzoni, Francesca Guerini, Marco Ramera, Paola Bertocchi, Francesca Aroldi, Alberto Zaniboni, Edoardo Rosso

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report

    Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report oleh Francesca Aroldi, Paola Bertocchi, Fausto Meriggi, Chiara Abeni, Chiara Ogliosi, Luigina Rota, Claudia Zambelli, Claudio Bnà, Alberto Zaniboni

    Diterbitkan 2014-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

    421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in pat... oleh Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Howard Kaufman, Suzanne Thomas, Praveen Bommareddy, Francesca Aroldi, Pablo Nanclares, Lavita Menezes, Selda Samakoglu

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors

    507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced s... oleh Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Andrea Pirzkall, Praveen Bommareddy, Isla Leslie, Francesca Aroldi, Pablo Nenclares, Tze Chan, Imran Saleem, Henry Castro

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

    A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) oleh Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Lucinda Griffiths, Cathy Qi, Matthew Parkes, Simon Lord, Gareth J. Veal, David J. Harrison, Vicky M. Coyle, Jill Graham, Thomas R. Jeffry Evans, Sarah P. Blagden

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors

    506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors oleh Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Jason Chesney, Mohammed Milhem, Kevin Harrington, Robert Coffin, Katy Tsai, Adel Samson, Bartosz Chmielowski, Ari VanderWalde, Andrea Pirzkall, Jiaxin Niu, Praveen Bommareddy, Georgia Beasley, Gino In, Terence Rhodes, Francesca Aroldi, Lavita Menezes, Tawnya Bowles, Hamid Emamekhoo, Scott Baum, Sophie Dalac-Rat, Katharina Kahler, Eva Muñoz

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: